RxDoctor Payments DataLook up a doctor →

Carlo Hatem, MD

Critical Care Medicine · El Paso, TXNPI 1295814705

Payments from drug & device makers

$1,561,665in general payments, 2019–2025

Across 557 payments — averaging $2803.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$784K
  • AstraZeneca$451K
  • Teva Pharmaceuticals USA, Inc.$59K
  • Astrazeneca UK Limited$47K
  • CSL Behring$41K
  • Sanofi US Services Inc.$38K
  • plus $142K from 41 others

What the payments were for

  • Travel & lodging$1,09010%
  • Food & beverage$7,89275%
  • Education$1,58015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561,665 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$361,739
Medicare patients
702
Services billed
6,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate80$969,403
Trelegy ElliptaFluticasone/Umeclidin/Vilanter369$403,241
Breztri AerosphereBudesonide/Glycopyr/Formoterol96$93,154
XolairOmalizumab22$91,619
Breo ElliptaFluticasone/Vilanterol129$90,993
Ambrisentan12$85,014
Fasenra PenBenralizumab12$72,813
Spiriva RespimatTiotropium Bromide67$65,444
NucalaMepolizumab12$50,618
Pirfenidone16$40,568
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$25,423
Fluticasone-SalmeterolFluticasone Propion/Salmeterol131$25,044
SymbicortBudesonide/Formoterol Fumarate55$22,516
Combivent RespimatIpratropium/Albuterol Sulfate21$15,149
Incruse ElliptaUmeclidinium Bromide14$12,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$34,128$1,049,997168 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$32,121$583,212548 claims
AstraZenecaBreztri Aerosphere, Symbicort$450,543$115,670151 claims
Genentech, Inc.Xolair$784,038$91,61922 claims
PfizerEliquis$11,718$9,54516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →